Sudeep Pharma Intrinsic Value
Sudeep Pharma (SUDEEPPHRM) median intrinsic value is ₹814.45 from 9 valuation models (range ₹333–₹2217), vs current price ₹1108.40 — -26.5% downside (Trading Above Calculated Value), margin of safety -36.1%. For current market price and key ratios, visit Sudeep Pharma stock price NSE.
SUDEEPPHRM Valuation Methods Summary — DCF, Graham Number & P/E
Sudeep Pharma intrinsic value across 9 models vs current price ₹1108.40 — upside/downside and value range per method. Analyse Sudeep Pharma shareholding analysis to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹385.44 | ₹308.35 - ₹462.53 | -65.2% | EPS: ₹17.52, Sector P/E: 22x |
| Book Value Method | asset | ₹1632.73 | ₹1469.46 - ₹1796.00 | +47.3% | Book Value/Share: ₹816.36, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1374.55 | ₹1237.10 - ₹1512.01 | +24.0% | Revenue/Share: ₹687.27, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2216.80 | ₹1995.12 - ₹2438.48 | +100.0% | EBITDA: ₹276.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹814.45 | ₹651.56 - ₹977.34 | -26.5% | CF Growth: 13.4%, Discount: 15% |
| PEG Ratio Method | growth | ₹332.52 | ₹299.27 - ₹365.77 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹332.52 | ₹299.27 - ₹365.77 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2216.80 | ₹1995.12 - ₹2438.48 | +100.0% | ROE: 21.8%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹567.28 | ₹510.55 - ₹624.01 | -48.8% | EPS: ₹17.52, BVPS: ₹816.36 |
SUDEEPPHRM Intrinsic Value vs Market Price — All Valuation Models
Sudeep Pharma fair value range ₹333–₹2217 vs current market price ₹1108.40 across 9 valuation models. Read SUDEEPPHRM dividend growth for the complete payout history and dividend yield track record.
SUDEEPPHRM Intrinsic Value Analysis — Undervalued or Overvalued?
Sudeep Pharma median intrinsic value ₹814.45, current price ₹1108.40 — Trading Above Calculated Value by 26.5%, margin of safety -36.1%.
What is the intrinsic value of SUDEEPPHRM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sudeep Pharma (SUDEEPPHRM) is ₹814.45 (median value). With the current market price of ₹1108.40, this represents a -26.5% variance from our estimated fair value.
The valuation range spans from ₹332.52 to ₹2216.80, indicating ₹332.52 - ₹2216.80.
Is SUDEEPPHRM undervalued or overvalued?
Based on our multi-method analysis, Sudeep Pharma (SUDEEPPHRM) appears to be trading above calculated value by approximately 26.5%.
SUDEEPPHRM Financial Health — Key Ratios vs Industry Benchmarks
Sudeep Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.32 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 21.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 34.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.64x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SUDEEPPHRM Cash Flow Quality — Operating & Free Cash Flow
Sudeep Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹70 Cr | ₹-94 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹49 Cr | ₹10 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹66 Cr | ₹42 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹48 Cr | ₹23 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹-3 Cr | ₹-22 Cr | Negative Cash Flow | 3/10 |